<SEC-DOCUMENT>0001104659-20-048783.txt : 20200420
<SEC-HEADER>0001104659-20-048783.hdr.sgml : 20200420
<ACCEPTANCE-DATETIME>20200420172653
ACCESSION NUMBER:		0001104659-20-048783
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200419
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200420
DATE AS OF CHANGE:		20200420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		20803423

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2016414d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event
reported): April 19, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Connell Drive, Suite 1500<BR>
Berkeley Heights, NJ 07922<BR>
(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). <FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 1.01</B></TD><TD STYLE="text-align: justify"><B>Entry into a Material Definitive Agreement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 19, 2020, Cyclacel
Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;) entered into a Material Transfer Agreement (the &ldquo;<B>MTA</B>&rdquo;)
with The University of Edinburgh (&ldquo;<B>Edinburgh</B>&rdquo;). The main objective of the MTA is to study fadraciclib (CYC065)
and seliciclib (CYC202 or R-roscovitine), the Company&rsquo;s clinical stage CDK2/9 inhibitors, as potential early treatments for
the inflammatory response observed in patients with COVID-19 disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms
of the MTA, the parties will assess the Company&rsquo;s medicines mentioned above for their suitability for use in safety and
experimental medicine studies in COVID-19 patients (the &ldquo;<B>Evaluation</B>&rdquo;). The Evaluation is part of a broader
project (&ldquo;<B>STOPCOVID</B>&rdquo;) studying the inflammatory pathways that lead directly to COVID-19 lung injury.
STOPCOVID is supported by a &pound;2 million (approximately $2.5 million) grant from LifeArc, a medical research charity.
Edinburgh is seeking further funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MTA shall remain
in effect for the duration of the Evaluation. Additionally, each of the Company and Edinburgh may terminate the MTA if the other
party commits a breach of its obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary
of the MTA does not purport to be complete and is qualified in its entirety by reference to the MTA, which will be filed as an
exhibit to the Company&rsquo;s quarterly report on Form 10-Q for the quarter ending June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD STYLE="text-align: justify"><B>Other Events</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 20, 2020,
the Company issued a press release announcing that the Company had entered into the MTA described in Item 1.01 above. A copy of
the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 90%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><U>Exhibits</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 0.9in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit No.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"></P></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U STYLE="text-decoration: none">Description</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"></P></TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 3pt; text-align: center"><A HREF="tm2016414d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="padding-top: 3pt"></TD><TD STYLE="padding-top: 3pt"><A HREF="tm2016414d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release of Cyclacel Pharmaceuticals, Inc., dated April 20, 2020.</A></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: April 20, 2020</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2016414d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 70%"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 30%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel Pharmaceuticals, Inc.</P>


</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: rgb(167,167,167) 1pt solid; padding-bottom: 3pt; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 3pt"><B>CYCLACEL PHARMACEUTICALS
ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF EDINBURGH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>TO STUDY ITS CDK INHIBITORS TO REDUCE RUNAWAY INFLAMMATION IN COVID-19 DISEASE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 3pt"><B>-Evaluation of
Fadraciclib and Seliciclib to Promote Apoptosis of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Berkeley
Heights, NJ and Dundee, UK, April 20, 2020 </B></FONT>- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot;
or the &quot;Company&quot;) a biopharmaceutical company developing innovative medicines today announced that it entered into an
agreement with the University of Edinburgh to study fadraciclib (CYC065) and seliciclib (CYC202 or R-roscovitine), its clinical
stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The parties will
assess Cyclacel&rsquo;s medicines above for their suitability for use in safety and experimental medicine studies in COVID-19
patients. This evaluation is part of a broader project (&ldquo;<FONT STYLE="color: blue"><U>STOPCOVID</U></FONT>&rdquo;) studying
the inflammatory pathways that lead directly to COVID-19 lung injury, drawing upon more than 30 years of experience from the University
of Edinburgh&rsquo;s Centre for Inflammation Research. STOPCOVID is supported by a &pound;2 million (approximately $2.5 million)
grant from LifeArc and the University is seeking further funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;We are eager to evaluate the potential role
of Cyclacel&rsquo;s CDK inhibitors as enablers of inflammatory neutrophil apoptosis,&rdquo; said Professor Kev Dhaliwal, STOPCOVID
lead and Consultant in Respiratory Medicine at The University of Edinburgh. &ldquo;Clinical data from international studies suggest
that an early peripheral blood neutrophil response is associated with a poor outcome in COVID-19. If we can stop the inflammatory
cascade early, we may be able to prevent or delay the severity of COVID-19 induced inflammation and the need for assisted ventilation
in affected patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Previously published research from The University of Edinburgh
and other investigators have found that CDK inhibitors, including seliciclib, help resolve undesirable inflammation by promoting
apoptosis of inflammatory neutrophils. CDK inhibitors were shown to reduce levels of the anti-apoptotic protein Mcl-1 and inhibit
transcription of interleukin-6 (IL-6), both of which are believed to be drivers of the overactive systemic inflammatory response
severely damaging the lungs of symptomatic COVID-19 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;Our published
research showed that the CDK2/9 inhibitor seliciclib, induced human neutrophil apoptosis possibly by suppressing levels of the
Mcl-1 anti-apoptotic protein and augmented resolution of inflammation in 'neutrophil dominant' models,&rdquo; said Prof. Adriano
G. Rossi, Chair of Respiratory and Inflammation Pharmacology and Deputy Director of the Centre for Inflammation Research. &ldquo;We
are interested in extending these observations with fadraciclib, a second generation CDK inhibitor, as part of our STOPCOVID project
and possibly translating our findings to benefit COVID-19 patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;We are excited
to be contributing fadraciclib and seliciclib to the global effort to combat COVID-19,&rdquo; said Spiro Rombotis, President and
Chief Executive Officer of Cyclacel. &ldquo;As previously reported, our two investigational CDK inhibitors suppress Mcl-1 in patients
with proliferative diseases. Seliciclib has also been shown to efficiently suppress IL-6 transcription, a presumptive contributor
to COVID-19 cytokine storm. Seliciclib is active in models of lung injury, pleurisy and rheumatoid arthritis and is undergoing
clinical investigation in patients with rheumatoid arthritis. We are looking forward to working with The University of Edinburgh
team and are humbled by the possibility of helping COVID-19 patients in need.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&thorn;</FONT><FONT STYLE="font-size: 8pt">&nbsp;200
Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&#168;</FONT><FONT STYLE="font-size: 8pt">&nbsp;1
James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; color: blue"><U>www.cyclacel.com
</U></FONT> <FONT STYLE="font-size: 8pt">&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif; color: blue"><U>info@cyclacel.com</U></FONT></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About COVID-19 Respiratory Distress &amp; Cytokine Storm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
COVID-19 infected patients experience mild respiratory problems. Some hospitalized patients require mechanical ventilation
because of severe hypoxia and acute lung injury which may lead to rapid decline of respiratory function and death. This
condition, often called acute respiratory distress syndrome (ARDS), is thought to be associated with a systemic inflammatory
response of the immune system (cytokine storm). Clinical correlates of mortality from an analysis of 150 <FONT STYLE="color: blue"><U>Chinese
patients</U></FONT></FONT> include old age, sepsis, elevated d-dimer, and increased inflammatory parameters including IL-6
and CRP (C-reactive protein).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Anti-IL-6 Antibodies as Potential Treatment for COVID-19</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0">IL-6 is produced, along with
other cytokines, by the immune system in response to COVID-19 infection and contributes to antiviral defense through the
stimulation of a local and general immune response. Once triggered continued synthesis of IL-6 has pathological consequences
through chronic inflammation. <FONT STYLE="color: blue"><U>Evidence</U></FONT> points to an association of peak levels of
IL-6 with the severity of respiratory symptoms. Humanized anti- IL-6 receptor antibodies, including tocilizumab and
sarilumab, have been proposed as potential treatments to attenuate the overactive immune response and have begun evaluation
in COVID-19 patients ( <FONT STYLE="color: blue"><U>NCT04317092</U></FONT> and <FONT STYLE="color: blue"><U>NCT04327388</U></FONT>).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Published interim data from a small, uncontrolled <FONT STYLE="color: blue"><U>Chinese
study</U></FONT> suggest that IL-6 may be driving the inflammatory immune response that causes ARDS in seriously ill COVID-19
patients. The study showed that treatment with tocilizumab, a humanized anti IL-6 receptor antibody, in 15 of the 20 patients
on study resulted in reduced need for oxygen support and improved CRP levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About CDK Inhibitors as Potential Treatment for COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">The objective of treating
COVID-19 patients with transcriptionally-active cyclin- dependent kinase (CDK) inhibitors is to dampen the overactive immune
response in which activated inflammatory neutrophils may contribute. Neutrophil survival is promoted by Mcl-1 expression. <FONT STYLE="color: blue"><U>Rossi&nbsp;et&nbsp;al </U></FONT>showed
that seliciclib induced Mcl-1 downregulation and apoptosis of inflammatory neutrophils in models of acute lung injury,
arthritis and pleurisy. <FONT STYLE="color: blue"><U>Raje&nbsp;et&nbsp;al</U></FONT> showed that seliciclib inhibited
transcription and secretion of IL-6 triggered by multiple myeloma cells adhering to bone marrow stromal cells. Further it was
shown that seliciclib was more effective than anti-IL-6 antibody at suppressing Mcl-1 expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the TRAFIC Clinical Study of Seliciclib in Patients
with Rheumatoid Arthritis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seliciclib
is being tested in patients with refractory rheumatoid arthritis (RA) in an investigator-sponsored study (&lsquo;<FONT STYLE="color: blue"><U>TRAFI</U></FONT></FONT><U><FONT STYLE="color: blue">C</FONT></U>&rsquo;)
led by Prof. J. Isaacs and colleagues at Newcastle University and five other UK hospitals. TRAFIC is evaluating seliciclib&rsquo;s
potential to help patients with RA by means of reducing proliferation of synovial fibroblasts. As previously reported the TRAFIC
Independent Data Monitoring Committee recommended that the study should continue to its second stage which is currently enrolling.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology.
The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax
in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of
sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An IST is evaluating an oral combination of sapacitabine
and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced
leukemias/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology
based on a pipeline of novel drug candidates. For additional information, please visit <FONT STYLE="color: #0000ed"><U>www.cyclacel.com</U></FONT>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
 &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the <FONT STYLE="font-family: Times New Roman, Times, Serif">Securities and Exchange Commission and are available at <FONT STYLE="color: blue"><U>www.sec.go</U></FONT></FONT><U><FONT STYLE="color: blue">v</FONT></U>.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><B>References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Rossi AG, et al, Nature Med, 2006 Sept; 12(9): 1056-1064.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Raje N, et al, Blood, 2005 Aug 1; 106(3): 1042&ndash;1047.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Ruan Q, et al, Intensive Care Med, 2020 https://doi.org/10.1007/s00134-020-05991-x.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Hou T, et al, JBC, 2007 282:37091-37102.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Leitch AE, et al, Cell Death Differ, 2012 Dec; 19(12):1950-61.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Lucas CD, et al, Mucosal Immunol, 2014 Jul; 7(4): 857&ndash;868.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 3pt; width: 0in"></TD><TD STYLE="padding-top: 3pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD><TD STYLE="padding-top: 3pt; text-align: justify">Dzhagalov I, et al, Blood, 2007 Feb 15; 109(4): 1620&ndash;1626.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Company: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul McBarron, (908) 517-7330, <FONT STYLE="color: Blue"><U>pmcbarron@cyclacel.co</U></FONT></FONT><U><FONT STYLE="color: Blue">m
</FONT></U></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left; width: 1.15in">Public Relations: </TD>
    <TD STYLE="padding-top: 3pt; text-align: left">Russo Partners LLC, Nic Johnson, (212) 845-4242, <FONT STYLE="color: Blue"><U>Nic.Johnson@russopartnersllc.com</U></FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; text-align: left; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2e2e2e">Investor Relations:</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2e2e2e">Russo Partners LLC, </FONT>Jan Medina, (646) 942-5632,
<FONT STYLE="color: blue"><U>Jan.Medina@russopartnersllc.com</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&copy; Copyright 2020 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0.1pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0.1pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ ^@#Z  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< /H# 2(  A$! Q$!_\0
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MZKSI*3HQHT*LZ.%G-*A.MB(J5164H^U?\$Y_^"='A;7_  C9_M6?M5Z?!8>
M-'M[WQ5X"\#^-(FM=!UG3=*MCKDOQ2^)9U8V(OO"T%VD^J^'K749+6#5=/C7
M5[U)[(Z<;CCOVI?VY_CK^W)\0(?V<?V-M"\60_"N[EN--@B\'V=W8^(/B!8Q
MK%''KNOZI81V5[X%^'%E#([K;W$VG:/?6,UK_;DGF/;6E?1O_!4_XU^,?B_\
M3/AM_P $Y?@%I":GJ7B2Z\-3?$>QTMXDLI6OHOM'A/P7JT4#6\5CX9\.Z/9O
MXX\;07$BVL7AV'08 Q:[NHAH?$#Q'X-_X)>?#CPG^S%^S1HH^)'[:_QWM--7
M7?%KZ2^MZP^H73O91Z]?6< :YRMU<:C'\.O!S/#9"&UO=?UGS((+IIOV>AG&
M<9QG/#G'/%F78#BKQ!XIA'%>$W!6:U:&'X5X,X4PZJTL)Q1GL<5#ZK#+)8>A
M+$X;%X^E3JUZ6$Q+G-^UHV_G#&Y)DO!^0<3^&G!>=8G@_P -N!ZM' >-''.
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M2_-S=V*W.\(;V2QU>"$YE6RCF$5U _X:?L]>&_CAJ'@?X]?MA? #PO\ "/\
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M7QW\4_&_Q!U*6Q@CA;4K7QKJ?CF35O!NJ74B-)?K\.[CPGIY<M%:VD-FL,"
M'[":S\8?A?X=\!W?Q5UWXA>!=(^%UE:17MQ\1M0\7:)!X+CM9KQ+!+IO$PNG
MT06;WDB6<=P;_#WK"U""0@UU'A?Q9X=\;:!HWBOPAK>D^)O"WB*S@U/0?$6A
M:C;ZGH^L:7=1&6UU'3;^U:2VO;6X49CEMY)(V7YE=EK^;3_@M9^RG\%?V+?^
M#=S]K#]F[]G[PW?^%/@_X!TKPK+X+\,:KXBUSQ;/H5KX@_:$\&^*KBP@U[Q+
M>:CK]]:6NIZI=FQDU?4M2OX[81QW%_=2HT[?IC_P1?B4?\$H_P#@GP5)4_\
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M,?+Y><-(JM\LI$;@J2'C;<70LJQRN5B?^(__ ()0E3_P=3_\%?/W<0(TGXE
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M-MKRV?:*%  4 #G ''4DG\SDGWI:@BN(I4#)(KC+@LO(RCLC@D# *LI5AU#
M@C(-2;T]<_0$_P A[U/*UI:R6FBT5OEL=R]Y*2?,I)24HN\9)Z\R:;33W33:
M:ZB2G;&QP3T&!P2"0" >W!//4=1S7\77[-7C?1_@9_P=\?MW>"OBGI5GX=U/
M]JGX%>&(?@CK.L7.E68UZ73/@_\ "#6TB\-3WAWSZCX@M? ?C+3+>"VE@N)[
MKP_JEF\<_P J/_:'.ADB9%QN; 4E0X!R.2IX8#N&RI[@C-?AY_P5S_X(J_#W
M_@IG9_#?XK>#OB5KO[-W[:'P%U;1M5^"/[2GANRN+Z_TPZ'KEKK>GZ-XNTC3
M-1TBXU.RL-7B&M>'?$.CZCI.O^&-6BM[R*:_LHKW2[Y ?M]9A5B8*%&978[6
MWQEGPY\M\X9 254*%6,J8E4","K!5&Y(4^YQC.5//;.57\A7\KOAWQ=_P==?
M JQT_P"'.K_!7]@/]L"+2]-L=+TGXW-XSN/ 6L7THNYC%K7C729/$7@9;S5+
M:PA^RZHN@^$=+MIENX)XY=3U(W][<_M]^P0/V_)O@G<7/_!1R'X"6OQ\N_%^
ML7-KIO[.4>OCP#I/@1[73/[#TJ23Q%>7UU-KMO?+J#7MPMW=PO"8_*N'&, '
M\F?_  =<_L\V_P &_CA^R=^V3\!_'GBGX*_&K]J:\\9?L0_&G6_ UY=:;'XZ
M^&?BW0K321>>(!;O'<75Y'X2UW6?#>KV[.XUNSB\.W:+')H4%P/Z_OV)OV5_
MA)^Q7^R[\%/V9_@II$6D?#SX8>"]-L+'Y;==0UO6]1F;7/$GBW6IK:.%;W7O
M$_B+4M0US6[Z6-I;B[U -OVJ /QK_P"#B7_@GE^U3_P4!\)?L,:1^R]X#TKQ
MKJ'P4_:=/Q.^(4.J^+_#7@P:5X5&FZ=$MY;W/B25+349Q-%*LL%H9[EC"0EG
M<><H7^B?3+.\MM)TRUF3]_:V%C;R!^0DUI;+&AQ'(Z32Q7,:,TK%8I8_GCV@
M"@#^,?\ X-_/$EC\(?\ @M#_ ,%S_P!F?XBZ%I?AKXM?$+XVZ]\5O" U75+*
M/Q%J7A'2?BU\1=<ETC1[6X9+K5+*_P##/Q1\'>.+N.PDF6WTRWM6GC$9#K_:
MI%M"DKP">A)RNT"/:0Q.W:5*[5^4'..2<_SS?\%6?^"&5W^V3\:? G[<_P"Q
MQ\?-6_8[_P""@WPH2T_L+XI:79W=UX1^)EKHD2)H.F_$"#2YH+_1=7T^U#:3
M'XHTZUU_3]3T%[CP]XH\(>(K&6QFT?P2Q^)W_!V'X*@;X;ZC^S/_ ,$Z?B]>
MVUG%8V/QVMO'.H>&])U%[6WMX'UO7O"\OC?0[V6_U.17U&_MM/\ !^C6GVZ:
MZ6QM+>T6WMHP#Z]_X.6<#_@BE^V\/3P[\-P/;/Q=^'@'TSD@>I..M?4G_!%\
MC_AU%_P3XY_YM6^%7_J.V=?&O[=O[*W_  48_;!_X(>?%W]FSXS:'\'_ !_^
MWQ\4])T=-<T+X2ZI#X9^$S76G_&W2?%>CZ=H&K^,;G2A8P:%X&TJQ2>?5;V[
M6;6[:9DNKA)TEB_.S]F37O\ @Z-_98_9X^#'[.?@?_@GU^Q9K7A7X'_#CPU\
M.O#^I>(OC'HCZOJ^E^&[5-.M+C5S8?%VPM7NKFVA5KV.P%IN9A(LD<C,M ']
M3/[4_P ?O!G[*_[.?QH_:0^(-Y%9^$/@I\.O%7Q"U=Y<E;D:#I-U-9:8BAT,
MESJ^HM::59Q*ZO+>7D$:'<PK^"W_ ((7?\%IO^">W[)7A[]K_P#:'_;5\;?%
MI_VPOVR_VB?$'Q$^(-SH7P;\:>.-.T?X>VQ2_P#!VC6'B;3;:Y(#:WX@US5;
M^W.H3)#:CPY9K$LEF&;]K/\ @I/^SK_P6'_X*3_\$VOV8_V6_%WP)^'/PI^,
M/QJ_:!M=0_;MOO _Q3\*P^!?AY\$_AWXLO)O#6F:%IVJ>(=5U3Q>GC5[OPKX
M_NT\->)QJ>G7GP\E\-7EKJ%OXG-S8_TK?"#X9^'O@Q\+OA]\(O!5A#IG@[X8
M>"_#'@#PQ9QP06FS1/".BV6A::[I!YL;2O9V, GD*QO-<I/<D,DZ!0#^!;]F
M[_@JC^Q_X=_X.2;3XY_LG^-O%,G[-/\ P46\%^%OAS\?(O'O@77?A7'X7_:"
MU?4=5TC3I7'B34K*2\T^;6]"\)>)[SQ#<O!I%B/B-KEBUG=77AX3O]J?\'%-
M];? [_@L'_P1 _:M^(^I:CI7P(\,?$BV\*>)/%,EK?C0_!^J>%?BKX6UO5Y]
M2OFVZ!ITNJ:)XFM=1GBV0WTFD^&-0OF#65@JP?KA_P '"W_!-7XH_P#!2#]C
M#1]#_9YL!)^U+\!_BGX6^+'P*O(O$-GX3NY+J,_V5XGTNT\67VJ>'[3P]=OI
MTHUNPU"2[EFM=8T'2'M6ADN-]O[C\?/V"D_X*O\ _!-SX>? '_@HCX(F^&WQ
MOU/P9X0\0^.+WP1JF@ZOJ7PG_:)\+://H^I^-?A[J-A)J6B76CZEJEQJUU#H
MIU.>VU+PGKC:!JE[--$UT #]:K*[MK\VE]:2I<VL\(FM+NWFCEM[RUNH_-BO
M8I(2;6ZM;N%+::TNK9GWI( IVM(*U21E.1]X_P#H+5_)'\*O@%_P<V_\$X_#
MOASX(_!/Q=^R)_P4@_9U^'YTOP_\-[SXOW^K?#?XP:7X&T?3=/L]%\/W=YJW
MB/1/[*L='AB-A8VVI>+_ (C7&GV&GQP66J0Q-96D/ZJ_\$]]9_X+3>,OBIXL
M\5_\%'_!/[)'PE^"\GA*XM? 'PS^!.J:YXD^(5GXWEUZPNH=3\4>(+R;7=)E
MT*VT%-0TTVUCJUO+<7LL-])$%1-P!_']_P $L_\ @F?XC_X*&?MS?\%DI?#?
M[;W[1W['4GPE_:PG>\3X"ZI%IMMX\MO%WQ#_ &@4\WQ3G7=+,DOAM=!E31Y9
M;>6*V&N:@Z2F1RB_UY?\$TO^"4WBK_@GIXU^)GBGQ)^W?^TU^US#\0O!^@>$
M8/#/QYOTNM$\)KX?U0WUOJ_AY5UG57AO[U;F.PNIH]IFM0B2O)(BA?Y\/V6O
MV.O^#@__ ()Q?M3?\%!/B9^RA^QQ^SA\2_!?[7GQVU7QRE[\5OC!X3$MOH'A
M[QU\1=7\&7&D66E_$7PO<V?VO2O'UP+RVU&UEN5:!7!5D0C]Y/\ @GS\8_\
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MXD6VM>,M&CM]"U"XT)=&TRU^)?BB6ZDOO$$>FV5PITAXTM)YY7N;8QJS ']
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = ?L# 2(  A$! Q$!_\0
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MSW+D@(%)QSG- '<PRI/$LL;AT<94CH14E9GA^VFM=%MXIP0^"=I_A!.0*TZ
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..R9W!< 9Q78CI110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
